Retatrutide: The Triple Agonist Peptide Explained

Retatrutide (LY3437943) is a first-in-class triple agonist peptide developed by Eli Lilly that simultaneously activates three metabolic receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and the glucagon receptor. This triple-receptor approach distinguishes it from single agonists like semaglutide and dual agonists like tirzepatide, and has produced the most significant weight reduction data observed in any clinical peptide trial to date.

The Evolution from Single to Triple Agonism

The progression of incretin-based peptide research follows a clear trajectory:

• First generation (single agonists): Semaglutide, liraglutide, and exenatide target only the GLP-1 receptor. Clinical data shows 15-17% mean weight reduction.
• Second generation (dual agonists): Tirzepatide activates both GLP-1 and GIP receptors. Phase 3 data demonstrated up to 22.5% weight reduction (SURMOUNT-1).
• Third generation (triple agonists): Retatrutide adds glucagon receptor activation to the dual agonist framework. Phase 2 data showed up to 24.2% weight reduction at 48 weeks.

Each additional receptor target adds distinct metabolic effects that compound the overall response.

Mechanism of Action: Three Receptors, Three Pathways

GLP-1 Receptor Agonism

The GLP-1 component drives appetite suppression through central nervous system pathways, glucose-dependent insulin secretion from pancreatic beta cells, and delayed gastric emptying. This is the same mechanism validated by semaglutide and forms the foundation of the compound's metabolic effects.

GIP Receptor Agonism

Glucose-dependent insulinotropic polypeptide (GIP) is the other major incretin hormone. GIP receptor activation enhances insulin secretion (complementary to GLP-1), may improve lipid metabolism through direct effects on adipose tissue, and has been associated with reduced nausea compared to GLP-1-only compounds. The inclusion of GIP agonism follows the same rationale validated by tirzepatide.

Glucagon Receptor Agonism

The glucagon component is what makes retatrutide unique. Glucagon receptor activation stimulates:

• Hepatic lipid oxidation: Glucagon increases fatty acid oxidation in the liver, reducing hepatic fat content.
• Thermogenesis: Glucagon increases energy expenditure through activation of brown adipose tissue and uncoupling protein pathways.
• Amino acid catabolism: Glucagon promotes gluconeogenesis from amino acids, which may contribute to overall metabolic rate increase.

The counterintuitive aspect of including glucagon (traditionally viewed as a glucose-raising hormone) is that its hyperglycemic effects are offset by the potent insulin-stimulating actions of the GLP-1 and GIP components. The net result in clinical observation has been improved glycemic control alongside the added metabolic benefits of glucagon signaling.

Phase 2 Clinical Trial Data

The pivotal Phase 2 trial (published in the New England Journal of Medicine, 2023) enrolled 338 adults with obesity. Key findings at 48 weeks:

• Highest dose group (12 mg): 24.2% mean body weight reduction
• Mid-dose group (8 mg): 22.8% mean reduction
• Lower dose group (4 mg): 17.5% mean reduction
• Placebo: 2.1% reduction

Notably, 100% of participants in the 12 mg group achieved at least 5% weight loss, and 83% achieved at least 15% weight loss. These response rates exceed those observed in published tirzepatide and semaglutide trials at comparable timepoints.

Hepatic Fat Reduction

A particularly significant finding was the effect on liver fat. In a sub-study using MRI-proton density fat fraction, participants receiving retatrutide demonstrated an 82.4% relative reduction in hepatic fat content at 48 weeks. This has implications for MASH (metabolic dysfunction-associated steatohepatitis) research, a condition with limited approved treatments.

Retatrutide vs Semaglutide: Key Differences

• Receptor targets: Retatrutide activates 3 receptors; semaglutide activates 1
• Weight reduction: Retatrutide showed ~24% at 48 weeks (Phase 2); semaglutide showed ~15% at 68 weeks (Phase 3)
• Energy expenditure: Retatrutide increases thermogenesis via glucagon; semaglutide does not
• Liver fat: Retatrutide showed 82% reduction; semaglutide showed ~40% in comparable studies
• Clinical stage: Retatrutide is in Phase 3; semaglutide is FDA-approved
• Administration: Both are once-weekly subcutaneous injection in clinical protocols

Current Research Status

Eli Lilly initiated Phase 3 trials (TRIUMPH program) in 2023 for obesity and type 2 diabetes indications. Results are expected in 2025-2026. Additional investigations are exploring retatrutide in MASH and chronic kidney disease.

Viking Labs offers research-grade Retatrutide in 10mg and 20mg vials at 99% purity for qualified research institutions.

Conclusion

Retatrutide represents the current frontier of incretin-based peptide research. By engaging three metabolic receptors simultaneously, it addresses energy intake (GLP-1), insulin sensitivity (GIP), and energy expenditure (glucagon) in a single compound. Phase 2 data suggests it may surpass all existing single and dual agonists in efficacy, though Phase 3 results and long-term safety data remain forthcoming.

*For laboratory research use only. Not for human consumption. These products are not drugs, supplements, or intended to diagnose, treat, cure, or prevent any disease.*